XNAS
BRVE
Market cap1.65bUSD
Sep 24, Last price
23.37USD
1D
8.90%
IPO
-22.10%
Name
Braveheart Bio Inc
Chart & performance
P/E
—
P/S
—
EPS
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
Net income
CFO
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Key people
Travis Murdoch
President, Chief Executive Officer · since 2024
Paul Rickey
Chief Financial Officer · since 2024
Marc Evanchik
Senior Vice President - Pharmacology and Translational Medicine · since 2024
Natalie Dement
Vice President, Head - Legal · since 2024
Amy Feng
Vice President - Biometrics and Data Management · since 2024
Valuation
No data to show